Edgewise Therapeutics (EWTX) Stock Forecast & Price Target

Edgewise Therapeutics is viewed positively because EDG-7500’s 12-week Phase 2 CIRRUS-HCM data showed broad efficacy in both oHCM and nHCM, including roughly 55% and 65% reductions in key hemodynamic and biomarker measures, alongside strong symptom gains and no LVEF decline below 50% across 53 patients. The investment case is further strengthened by the Servier transaction, which delivered $1.55 billion upfront and up to $1.1 billion in milestones, materially reducing financing and dilution risk while funding EDG-7500 through potential approval and sharpening the company’s cardiovascular focus. In addition, the preserved LVEF, GLS, and GCS profile across more than 240 exposed individuals and more than 700 echocardiograms supports a differentiated, potentially easier-to-use HCM therapy with meaningful commercial upside.

Edgewise Therapeutics is a clinical-stage company whose bearish case is driven by EDG-7500’s uncertain ability to differentiate in HCM, where aficamten has already launched successfully in nHCM and may capture first-mover share before Phase 3 completion. The excerpt also highlights meaningful execution and regulatory risk: only 53 patients have been treated for 12 weeks, larger pivotal trials must reproduce efficacy and safety, and the FDA could still require a REMS or echocardiographic monitoring that would blunt commercialization. Financially, the downside view is amplified by competitive pressure, reimbursement uncertainty, and reliance on the Servier transaction, with the stock potentially trading at cash, about $10, if the '7500 program disappoints.